From Pandemic Profits to Pioneering Cancer Cures: BioNTech’s Bold Future
BioNTech is transitioning from COVID-19 vaccine production to focus on cancer therapeutics, using its mRNA technology. Q4 2024 financial results show decreased profits and revenue; earnings per share dropped to…